The system will be unavailable for updates from 12:30 on Tuesday 23 May to prepare for the upgrade of the software platform.

Oral midazolam in paediatric premedication

Payne, K. A. ; Coetzee, A. R. ; Mattheyse, F. J. ; Dawes, T. (1991)

CITATION: Payne, K. A., et al. 1991. Oral midazolam in paediatric premedication. South African Medical Journal, 79:372-375.

The original publication is available at


In a premedication study involving 135 children, aged 1-10 years, four regimens were investigated: (i) no premedication; (ii) oral trimeprazine tartrate 2 mg/kg, methadone 0.1 mg/kg, droperidol 0.15 mg/kg (TMD); (iii) intramuscular midazolam (Dormicum; Roche) 0.15 mg/kg; and (iv) oral midazolam 0.45 mg/kg. All premedications were given 60 minutes before a standard halothane anaesthetic. No impairment of cardiovascular stability occurred but after premedication the mean oxygen saturation decreased by 1.6% and 1.1%, respectively, in the intramuscular midazolam and TMD groups. Overall, children under 5 years of age behaved less satisfactorily in the holding room and at induction, than those over 5 years (P<0.01). Midazolam, intramuscularly and orally, produced more satisfactory behaviour than the other two regimens (P<0.05) and, combined with a 70% more rapid recovery than the TMD regimen (P<0.05), suggests that oral midazolam is a more effective paediatric premedication agent than placebo or TMD.

Please refer to this item in SUNScholar by using the following persistent URL:
This item appears in the following collections: